Adjuvant PD-1 Antibody in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma After Chemoradiotherapy: a Multi-center, Randomised Controlled, Phase 3 Trial
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Camrelizumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 16 Jun 2018 Status changed from not yet recruiting to recruiting.
- 20 Apr 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jun 2018.
- 12 Feb 2018 New trial record